

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

MERCK SHARP & DOHME LLC,
Petitioner

v.

HALOZYME, INC.,
Patent Owner

Case PGR2025-00009
U.S. Patent No. 12,123,035

PATENT OWNER'S SIXTH MOTION TO SEAL

Mail Stop "PATENT BOARD"
Patent Trial and Appeal Board
U.S. Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

TABLE OF CONTENTS

I.	INTRODUCTION	1
II.	GOVERNING RULES AND PTAB GUIDANCE.....	1
III.	IDENTIFICATION OF CONFIDENTIAL INFORMATION	2
	A. Patent Owner’s Request for Director Review	2
IV.	GOOD CAUSE EXISTS FOR GRANTING HALOZYME’S MOTION TO SEAL	2
V.	CONCLUSION.....	3

I. INTRODUCTION

Pursuant to 37 C.F.R. §§ 42.14 and 42.54, Patent Owner Halozyme, Inc. (“Halozyme”) respectfully submits this Motion to Seal the confidential version of Patent Owner’s Request for Director Review of the Board’s Decision Denying Patent Owner’s Motion to Terminate (“Patent Owner’s Request for Director Review”), according to the terms of the Default Protective Order entered into this proceeding by the Board.

All of the allegedly confidential material belongs to Petitioner Merck Sharp & Dohme LLC (“Petitioner”) or its parent company Merck & Co., Inc. (collectively, “Merck”). The parties have met and conferred and Petitioner does not oppose this Motion.

II. GOVERNING RULES AND PTAB GUIDANCE

In determining whether to grant a motion to seal, the Board must find “good cause,” 37 C.F.R. § 42.54(a), and “strike a balance between the public’s interest in maintaining a complete and understandable file history and the parties’ interest in protecting truly sensitive information,” Consolidated Trial Practice Guide, November 2019 (“TPG”), 19. The Board identifies confidential information in a manner “consistent with Federal Rule of Civil Procedure 26(c)(1)(G), which provides for protective orders for ... confidential research, development, or commercial information.” *Id.*

Based on the procedure set forth in the TPG, Halozyme seeks to prevent the disclosure of information Petitioner has alleged is confidential.

III. IDENTIFICATION OF CONFIDENTIAL INFORMATION

Specifically, based on procedure provided in the TPG, Halozyme seeks to prevent the disclosure of information Petitioner has alleged is confidential contained in Patent Owner's Request for Director Review.

A. Patent Owner's Request for Director Review

Portions of Patent Owner's Request for Director Review contain information that Petitioner has marked as "PROTECTIVE ORDER MATERIAL." Based on Petitioner's representation that the information contained therein is indeed confidential, the information sought to be sealed has not been published or otherwise made public.

IV. GOOD CAUSE EXISTS FOR GRANTING HALOZYME'S MOTION TO SEAL

Petitioner has represented that public disclosure of information contained in Patent Owner's Request for Director Review would significantly harm Petitioner.

The public interest will not be harmed by granting this Motion to Seal. To the contrary, at least according to Petitioner's representations regarding the confidentiality of the underlying information, granting this Motion to Seal would achieve "a balance between the public's interest in maintaining a complete and understandable file history and the parties' interest in protecting truly sensitive

information.” 77 Fed. Reg. 48,755, 48,760 (Aug. 14, 2012). Therefore, good cause exists for granting this Motion to Seal.

V. CONCLUSION

For the foregoing reasons, Patent Owner respectfully requests that the Board seal the confidential version of Patent Owner’s Request for Director Review of the Board’s Decision Denying Patent Owner’s Motion to Terminate.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX PLLC

/Eldora L. Ellison/

Eldora L. Ellison, Ph.D.
Registration No. 39,967
Lead Attorney for Patent Owner

Date: May 26, 2026

1101 K Street, NW, 10th Floor
Washington, DC 20005
(202) 371-2600

CERTIFICATE OF SERVICE (37 C.F.R. § 42.6(e))

I certify that the above-captioned **PATENT OWNER'S SIXTH MOTION TO SEAL** was served in its entirety on May 26, 2026, upon the following parties via electronic mail:

Jeffrey P. Kushan (Lead Counsel)	jkushan@sidley.com
Leif Peterson (Back-up Counsel)	leif.peterson@sidley.com
Sue Wang (Back-up Counsel)	sue.wang@sidley.com
Katherine A. Helm (Back-up Counsel)	khelm@dechert.com
Amy Mahan (Back-up Counsel)	Amy.mahan@sidley.com
Blaine Hackman (Back-up Counsel)	Blaine.Hackman@dechert.com
Christine M. Engen (Back-up Counsel)	christine.engen@sidley.com
Amit Bhatla (Back-up Counsel)	abhatla@sidley.com
Brian M. Goldberg (Back-up Counsel)	Brian.Goldberg@dechert.com
Mark Stewart (Back-up Counsel)	mark.stewart@merck.com
	HalozymePGRs@sidley.com
	Merck-Halozyme-Dechert@dechert.com

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX PLLC

/Eldora L. Ellison/

Eldora L. Ellison, Ph.D.
Registration No. 39,967
Lead Attorney for Patent Owner

Date: May 26, 2026

1101 K Street, NW, 10th Floor
Washington, DC 20005
(202) 371-2600